In vitro antibacterial activity and pharmacodynamics of new quinolones

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 22, Issue 4, 2003, Pages 203-221

  Dalhoff, A ^a   Schmitz, F J ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; ENOXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BETA HEMOLYTIC STREPTOCOCCUS; DRUG DOSE; DRUG EFFICACY; ENTEROBACTERIACEAE; GENE MUTATION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SIMULATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE;

EID: 0038184157     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-003-0907-5     Document Type: Review

References (137)

1. Dabernat H, Delmas C (1998) Activite due Centre National de Reference des Haemophilus influenzae, annees 1996-1997: le declin du type b. Med Maladies Infectieuses 28:940-946
2. Jacobs MR, Bajaksouzian S (1997) Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid. Diagn Microbiol Infect Dis 28:105-112
3. Jorgensen JH (1992) Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 14:1119-1123
4. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, McGeer A, Moore TC, Witwicki E, the Canadian Haemophilus Study Group, Low DE (1994) Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. J Antimicrob Agents Chemother 38:1678-1680
5. Bell SM, Plowman D (1980) Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet i:279-280
6. Markowitz SM (1980) Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of Haemophilus influenzae. J Antimicrob Agents Chemother 17:80-83
7. Mendelman PM, Chaffin DO, Stull TL, Rubens CE, Mack KD, Smith AL (1984) Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae. J Antimicrob Agents Chemother 26:235-244
8. Offit PA, Campos JM, Plotkin SA (1982) Ampicillin-resistant, beta-lactamase-negative Haemophilus influenzae type b. Pediatrics 69:230-231
9. Doern GV, Jones RN, Pfaller MA, Kugler K, and the SENTRY Participants Group (1997) Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada 1997). J Antimicrob Agents Chemother 43:385-389
10. Clairoux N, Picard M, Brochu A, Rousseau N, Gourde P, Beauchamp D, Parr TR, Bergeron MG, Malouin F (1992) Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. J Antimicrob Agents Chemother 36:1504-1513
11. Seki H, Asahara Y, Ohta K, Ohta K, Saikawa Y, Sumita R, Yachie A, Fujita SI, Koizumi S (1999) Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 45:15-21
12. Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M (2001) Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. J Antimicrob Agents Chemother 45:1693-1699
13. Hoi-Dang AB, Brive-Le Bouguenec C, Barthelemy M, Labia R (1978) Novel beta-lactamase from Branhamella catarrhalis. Annu Rev Microbiol 129B:397-406
14. Felmingham D, Washington J (1999) Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother 11 [Suppl 1]:5-21
15. Wallace JR, Steingrube VA, Nash DR, Hollis DG, Flanagan C, Brown BA, Labidi A, Weaver RE (1989) BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in Branhamella catarrhalis, M. nonliquefaciens and M. lacunata. J Antimicrob Agents Chemother 33:1845-1854
16. Hausman D, Bullen MM (1967) A resistant pneumococcus. Lancet ii:264-265
17. Hausman D, Glasgow H, Sturb J, Devitt L, Douglas R (1971) Increased resistance to penicillin in pneumococci isolated from man. N Engl J Med 284:175-177
18. Tenover FC (2001) Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis 33 [Suppl 3]:108-115
19. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C (2000) Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Agents Chemother 45:457-466
20. Reinert RR, Al-Lahham A, Lemperle M, Tenholte C, Briefs C, Haupts S, Gerards HH, Lütticken R (2002) Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Agents Chemother 49:61-68
21. Whitney GG, Fawley MM, Hadler J, Harrison LH, Lexau C, Renigold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343:1917-1924
22. Foster DA, Heller ST, Young JK (2001) Multi-resistant Streptococcus pneumoniae. N Engl J Med 344:1329
23. Johnson AZ, Warner M, George RC, Livermore DM (2001) Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales. J Antimicrob Chemother 47:411-415
24. King A, May J, French G, Phillips I (2000) Comparative in vitro activity of gemifloxacin. J Antimicrob Chemother 45 [Suppl S1]:1-12
25. Milatovic D, Schmitz F-J, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102-1107
26. Bauernfeind A (1997) Comparison of the antimicrobial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40:639-651
27. Dalhoff A (1999) In vitro activities of quinolones. Exp Opin Invest Drugs 8:123-137
28. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, Bonner DP (2000) Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. J Antimicrob Agents Chemother 44:3351-3356
29. Fix AM, Pfaller MA, Biedenbach DJ, Beach ML, Jones RN (2001) Comparative antimicrobial spectrum and activity of BMS-284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents 18:141-145
30. Takahata M, Shimakura M, Hori R, Kizawa K, Todo Y, Minami S, Watanabe Y, Narita H (2001) In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 45:312-315
31. Boswell FJ, Andrews JM, Wise R (2000) Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 48:446-447
32. Bassetti M, Dembry LM, Farrel PA, Collan DA, Andriole VT (2002) Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother 46:234-238
33. Dalhoff A, Petersen U, Endermann R (1996) In vitro activity of BAY 12-8039, a new 8-methoxy quinolone. Chemotherapy 42:410-425
34. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Köhrer K, Schmitz F-J (2000) Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 44:462-466
35. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, Aguilar L, Garcia-de-Lomas J, Ruiz J, and the Spanish Surveillance Group for Respiratory Pathogens (SAUCE program) (2002) Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 46:2665-2667
36. Jones M, Critchley IA, Karlowsky JA, Blosser-Middeton RS, Schmitz FJ, Thornsberry C, Sahm DF (2002) In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 950994 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother 46:1651-1657
37. Schmitz FJ, Milatovic D, Boos M, Mayer S, Fluit AC (2002) In vitro activitiy of the novel des-F(6) quinolone BMS-284756 against genetically characterised clinical isolates including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 49:698-701
38. Weigel LM, Anderson GJ, Facklam RR, Tenover FC (2001) Genetic analysis of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:3517-3523
39. Schmitz F-J, Higgins PG, Mayer S, Fluit AC, Dalhoff A (2002) Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 21:647-659
40. Low DE, Müller M, Duncan CL, Willey BM, de Azavedo JC, McGeer A, Kreiswirth BM, Pong-Porter S, Bast DJ (2002) Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Antimicrob Agents Chemother 46:1119-1121
41. Schmitz F-J, Fluit C, Hafner D, Beeck A, Perdikouli M, Boos M, Scheurig S, Verhoef J, Köhrer K, von Eiff C (2000) Development of resistance to ciprofloxacin, rifampin and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 44:3229-3231
42. Dalhoff A (1999) Antistaphylococcal activity of moxifloxacin. Drugs 58 [Suppl 2]:8-9
43. Schedletzky H, Wiedemann B, Heisig P (1999) The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 43 [Suppl B]:31-37
44. MacGowan AP (1999) Moxifloxacin (BAY 12-8039): a new methoxy quinolone antibacterial. Exp Opin Invest Drugs 8:181-199
45. Mzali F, Nice C, Dalhoff A, Hawkey P (1999) Differential selection of quinolone resistance by new quinolones in methicillin-sensitive (MSSA) and -resistant (MRSA) Staphylococcus aureus. Clin Microbiol Infect 5 [Suppl 3]:119-120
46. Schmitz F-J, Fluit AC, Hafner D, Beek A, Perdikouli M, Boos M (2000) Development of resistance to ciprofloxacin, rifampin and mupirocin in methicillin-susceptible and -resistant Staphylococcus isolates. Antimicrob Agents Chemother 44:3229-3231
47. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM (2001) Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 48:375-381
48. Dalhoff A (2001) Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 32 [Suppl 1]:16-22
49. SENTRY Participants Group (Latin America), Gales A, Sader H, Jones RN (2001) Activities of BMS-284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999). Antimicrob Agents Chemother 45:1463-1466
50. Biedenbach DJ, Jones RN, Pfaller MA (2001) Activity of BMS284756 against 2,681 recent clinical isolates of Haemop influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagn Microbiol Infect Dis 39:245-250
51. Fuchs PC, Barry AL, Brown SD (1997) Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. J Antimicrob Chemother 39:671-673
52. Blondeau JM (1999) A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones". J Antimicrob Chemother 43 [Suppl B]:1-11
53. Jones RN, Barrett MS, Biedenbach DJ (1994) Interpretative criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Diagn Microbiol Infect Dis 19:93-99
54. Bauernfeind A, Jungerwirth R, Ratjen F (1999) Susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients to ciprofloxacin. Drugs 58 [Suppl 2]:209-210
55. Worlitzsch D, Dalhoff A, Döring G (1999) In vitro activity of fluoroquinolones against Staphylococcus aureus isolates from cystic fibrosis patients and Pseudomonas aeruginosa environmental strains. Drugs 58 [Suppl 2]:147
56. Goldstein EJC (2000) Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens. J Antimicrob Chemother 45 [Suppl S1]:55-65
57. Kleinkauf N, Ackermann G, Schaumann R, Rodloff AC (2001) Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 45:1896-1899
58. Ackermann G, Schaumann R, Pless B, Claros MC, Goldstein EJC, Rodloff AC (2000) Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 19:228-232
59. Hoellmann DB, Kelly LM, Jacobs MR, Appelbaum PC (2001) Comparative anti-anaerobic activity of BMS 284756. Antimicrob Agents Chemother 45:589-592
60. Hammerschlag MR (2000) Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother 45 [Suppl S1]:35-39
61. Dubois J, St-Pierre C (2000) Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J Antimicrob Chemother 45 [Suppl S1]:41-46
62. Rittenhouse S, McCloskey L, Broskey J, Niconovich N, Jakielaszek C, Poupard J, Coleman K (2000) In vitro antimicrobial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J Antimicrob Chemother 45 [Suppl S1]:23-27
63. Pendland SL, Losnedahl KJ, Schriever CA (1999) In vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp. J Antimicrob Chemother 44:295-297
64. Ullmann U, Schubert S, Krausse R (1999) Comparative in vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 43 [Suppl C]:33-36
65. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R (1997) In vitro study of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 40:639-651
66. Weller TMA, Andrews JM, Jevons G, Wise R (2002) The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 49:177-184
67. Dalhoff A, Ullmann U (1990) Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 9:479-487
68. Craig WA (1998) Pharmacokinetics/pharmacodynamics parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 26:1-12
69. Schentag JJ, Smith JL, Swanson DJ, De Angelis C, Vari A, Vance JW (1994) Role for dual individualization with cefmenoxime. Am J Med 77 [Suppl 6A]:43-50
70. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081
71. Thomas JK, Forrest A, Bhavnami SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521-527
72. Dudley MN, Ambrose PG (2000) Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints ready for primetime. Curr Opin Microbiol 3:515-521
73. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M (1998) Pharmacodynamics of levofloxacin; a new paradigm for early clinical trials. JAMA 279:125-129
74. Lacy ML, Lu W, Xu X, Niolau DP, Quintiliani R, Nightingale CH (1999) Pharmacodynamic comparisons of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43:79-86
75. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF (2001) Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae: analysis of phase III clinical trials. Antimicrob Agents Chemother 45:2793-2797
76. Lister PD, Sanders CC (1999) Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 43:1118-1123
77. Craig W, Dalhoff A (1998) Pharmacodynamics of fluoroquinolones in experimental animals. In: Kuhlmann J, Dalhoff A, Zeiler HJ (eds) Quinolone antibacterials. Springer, Berlin Heidelberg New York, pp 207-232
78. Drusano GL, Johnson DE, Rosen M, Standiford HC (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483-490
79. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060
80. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 155:93-99
81. Dalhoff A (1999) Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 43 [Suppl B]:51-59
82. Wise R (1983a) Protein binding of beta-lactams: the effects on activity and pharmacology, particularly tissue penetration, part I. J Antimicrob Chemother 12:1-18
83. Wise R (1983b) Protein binding of beta-lactams: the effects on activity and pharmacology, particularly tissue penetration, part II. J Antimicrob Chemother 12:105-118
84. Pankuch GA, Nagai K, Davies TA, Jacobs MR, Appelbaum PC (2002) Antipneumococcal activity of BMS 284756 compared to those of six other agents. Antimicrob Agents Chemother 46:251-254
85. Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC (2001) Single- and multistep resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48:365-374
86. Gonzalez MA, Uribe F, Duran Moisen S, Pichardo Fuster A, Selen A, Welling PG, Painter B (1984) Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741-744
87. Fish DN, Chow AT (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119
88. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE (1995) Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 36:385-394
89. Efthymiopoulos C (1997) Pharmacokinetics of grepafloxacin. J Antimicrob Chemother 40 [Suppl A]:35-43
90. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H (1995) Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone in humans. Antimicrob Agents Chemother 39:2635-2640
91. Stass H, Proeve A (1999) Pharmacokinetic/pharmacodynamic estimates for the treatment of community-acquired respiratory tract infections with moxifloxacin (MXF). Clin Microbiol Infect 5 [Suppl 3]:291-292
92. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M (1995) Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 39:170-174
93. Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC (2000) Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 44:1604-1608
94. st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract no. A-45
95. Wise R, Gee T, Marshall G, Andrews JM (2002) Single-dose pharmacokinetics and penetration of BMS 284756 into inflammatory exudate. Antimicrob Agents Chemother 46:242-244
96. MacGowan A, Rogers C, Bowker K (2000) The use of in vitro pharmacodynamic models of infection to optimise fluoroquinolone dosing regimens. J Antimicrob Chemother 46:163-170
97. Bauernfeind A, Petermüller C, Heinrich B, Gablac R (1986) Abhängigkeit von Bakterizide und Mutantenselektion bei 4-Chinolonen von deren Serumkonzentrationsverläufen. Infection 14 [Suppl 1]:26-30
98. Dalhoff A (1991) Clinical perspectives of quinolone resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:221-239
99. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM (1994) Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 38:2702-2709
100. Bauernfeind A (1993) Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 31:789-798
101. Thorburn CE, Edwards DI (2001) The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother 48:15-22
102. Lister PD, Sanders CC (2001) Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47:811-818
103. Lister PD (2001) Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 32 [Suppl 1]:33-38
104. th BICON, Hamburg, abstract no. T135
105. th International Symposium on New Quinolones, Denver, abstract no. P104
106. Dalhoff A (2001) Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 32 [Suppl 1]:16-22
107. Dalhoff A (1999) In vivo lack of emergence of resistance to moxifloxacin in Staphylococcus aureus and Streptococcus pneumoniae. In: Adam D, Finch R (eds) Moxifloxacin in practice. Maxim Medical, Oxford, pp 81-89
108. Fukuda H, Kishii R, Takei M, Hosaka M (2001) Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 45:1649-1653
109. th International Congress of Infectious Diseases, Boston, abstract no. 47.003
110. th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, abstract no. 102
111. st International Symposium on Resistant Gram-Positive Infections, San Antonio, abstract no. I-9
112. th International Symposium on New Quinolones, Denver, abstract no. P67
113. Boos M, Mayer S, Fischer A, Köhrer K, Scheuring S, Heisig P, Verhoef J, Fluit AC, Schmitz FJ (2001) In vitro development of resistance to six fluoroquinolones in Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob Agents Chemother 45:938-942
114. Schmitz FJ, Boos M, Meyer S, Hafner D, Jagusch H, Verhoef J, Fluit AC (2001) Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:2666-2667
115. Madaras-Kelly KJ, Daniels C, Haegbloom M, Thompson M (2002) Pharmacodynamic characterisation of efflux and topoisomerase IV mediated fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50:211-218
116. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR (2000) A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux. Antimicrob Agents Chemother 44:798-801
117. Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S (1996) Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 40:1835-1842
118. Boswell FJ, Andrews JM, Jevons G, Wise R (2002) Comparison of in vitro activities of several new quinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 50:495-502
119. Karlowsky JA, Draghi DC, Thomsberry C, Jones ME, Critchley IA, Sahm DF (2002) Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the U.S. Int J Antimicrob Agents 20:76-85
120. Hoban DJ, Doem GV, Fluit AC, Roussel-Delvallez M, Jones RN (2001) Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32:81-93
121. Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, and the L-S Group (2000) Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Jpn J Antibiot 53:387-408
122. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC (1977) Penicillin and chloramphenicol-resistant Streptococcus pneumoniae from clinical specimens. Lancet ii:995-997
123. Jacobs MR, Koornhof HJ, Robins-Porowne RM (1977) Emergence of multiply resistant pneumococci. N Engl J Med 299:735-740
124. Munshi MH, Haider K, Rahaman MM, Sack DA, Ahmed ZU (1987) Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet i:419-421
125. Martinez-Martinez L, Pascual A, Jacoby GA (1998) Quinolone resistance from a transferable plasmid. Lancet i:797-799
126. Courvalin P (1990) Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother 34:681-684
127. Rahman M, Mauff G, Levy J, Couturier M, Pulverer G, Glasdorff N, Bützler JP (1994) Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob Agents Chemother 38:2488-2491
128. Ashraf MM, Ahmed ZU, Sack DA (1991) Unusual association of a plasmid with nalidixic acid resistance in an epidemic strain of Shigella dysenteriae type 1 from Asia. Can J Microbiol 37:59-63
129. Tran JH, Jacoby GA (2002) Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 99:5638-5642
130. nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract no. C1-26
131. Hakenbeck R (1999) Beta-lactam-resistant Streptococcus pneumoniae: epidemiology and evolutionary mechanism. Chemotherapy 45:83-94
132. Ferrándiz MJ, Fenoll A, Linares J, De La Campa AG (2000) Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 44:840-847
133. Ferrándiz MJ, Oteo J, Aracil B, Gómez-Garcés JL, De La Campa AG (1999) Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother 43:2520-2523
134. González I, Georgiou M, Alcaide F, Balas D, Linares J, De La Campa AG (1998) Fluoroquinolone resistance mutations in the parC, parE and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 42:2792-2798
135. Bast DJ, De Azavedo JC, Tam TY, Kilburn L, Duncan C, Mandell LA, Davidson RJ, Low DE (2001) Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 45:2631-2634
136. Yokota S, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, Akizawa H, Himi T, Fujii N (2002) Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 46:3311-3315
137. Hooper D (2002) Fluoroquinolone resistance among gram-positive cocci. Lancet Infect Dis 2:530-538